Stoke Therapeutics Q4 Earnings Report Analysis

Monday, 25 March 2024, 22:02

Stoke Therapeutics outperformed expectations with a GAAP EPS of -$0.60, surpassing estimates by $0.02. However, the revenue of $2.8M fell short by $0.42M. The Q4 financial results provide insights into Stoke Therapeutics' performance and financial health.
LivaRava Finance Meta Image
Stoke Therapeutics Q4 Earnings Report Analysis

Stoke Therapeutics Q4 Earnings Report

Stoke Therapeutics posted a GAAP EPS of -$0.60, exceeding estimates by $0.02, while the revenue of $2.8M missed expectations by $0.42M.

Key Points:

  • Positive: Beat on GAAP EPS
  • Negative: Miss on Revenue

The Q4 report highlights the company's financial performance and future outlook.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe